International Flavors & Fragrances

“also announced an agreement to sell our soy crush concentrates and lecithin businesses to Bunge, which we expect to happen by April.”

IFF agreed to divest its soy crush concentrates and lecithin businesses to Bunge, expected to close by April 2026, as part of its portfolio optimization.

“winning a Miu Miu by L'Oreal Fine Fragrance”

IFF won the Miu Miu by L'Oreal fine-fragrance mandate, a read-through of L'Oreal fragrance-launch activity and IFF's win rate with a key customer.

“announced the divestiture of our Soy Crush, Concentrates & Lecithin business to Bunge, which is aligned with our margin enhancement strategy.”

IFF is divesting its Soy Crush, Concentrates & Lecithin business to Bunge, a small bolt-on acquisition for Bunge's oilseeds platform.

“we announced a joint venture with Kemira to provide high-performance, sustainable alternatives to fossil fuel-based ingredients, also utilizing our DEB technology.”

IFF's joint venture with Kemira (AlphaBio) is building a DEB biomaterial plant for sustainable ingredient alternatives, targeting 2027 start-up.

“We recently announced an exciting strategic collaboration with BASF to drive next-generation enzyme and polymer innovation, including our Designed Enzymatic Biomaterial or DEB technology.”

IFF formed a strategic collaboration with BASF combining IFF enzymes/DEB technology with BASF chemistry for home and personal care markets.

“I think Athletic Greens is an example or Fairlife as an example, now owned by Coke is driving great growth with their core power products.”

IFF cites Athletic Greens as an example of a smaller company succeeding with innovative products, part of a market dynamic where local and challenger brands are competing effectively against global multinationals.

“I think Athletic Greens is an example or Fairlife as an example, now owned by Coke is driving great growth with their core power products.”

IFF cites Coca-Cola-owned Fairlife as an example of a smaller, innovative brand driving strong growth with its core power protein products, illustrating the kind of nimble competitor gaining share from larger multinationals.

“we also announced the divestiture of our Soy Crush, Concentrates and Lecithin business to Bunge. These products better fit with Bunge, and it's another step in our focus on products with differentiated innovation that enhances margins.”

IFF divested its commoditized soy crush, concentrates and lecithin business to Bunge, which management said is better positioned to run those low-margin commodity products.

“First of all, this Alpha Bio JV with Kemira is a 50/50 JV and it's around scaling our design enzymatic biomaterials, the DEB technology which is breakthrough technology and it's ready to go.”

IFF and Kemira formed a 50/50 joint venture (Alpha Bio) to build a EUR130 million plant in Finland scaling IFF's enzymatic biomaterials technology for water treatment and packaging end markets.

“we also completed our previously announced divestiture of Pharma Solutions to Roquette two months ahead of our publicly announced schedule.”

IFF sold its Pharma Solutions business to Roquette, closing two months early; proceeds helped IFF reach its net debt to credit-adjusted EBITDA target below 3x.